SUTRO BIOPHARMA, INC. Share-based Payment Arrangement, Expense
SUTRO BIOPHARMA, INC. (STRO) reported Share-based Payment Arrangement, Expense of $2.01 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-12
- SUTRO BIOPHARMA, INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $2.01M, a 61.81% decline year-over-year.
- SUTRO BIOPHARMA, INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $1.56M, a 71.79% decline year-over-year.
- SUTRO BIOPHARMA, INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $1.66M, a 72.02% decline year-over-year.
- SUTRO BIOPHARMA, INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $1.55M, a 76.29% decline year-over-year.
- SUTRO BIOPHARMA, INC. share-based payment arrangement, expense for fiscal 2025 was $14.01M, a 43.26% decline from fiscal 2024.
- SUTRO BIOPHARMA, INC. share-based payment arrangement, expense for fiscal 2024 was $24.69M, a 0.89% decline from fiscal 2023.
- SUTRO BIOPHARMA, INC. share-based payment arrangement, expense for fiscal 2023 was $24.91M, a 5.31% decline from fiscal 2022.
- SUTRO BIOPHARMA, INC. share-based payment arrangement, expense for fiscal 2022 was $26.30M, a 13.18% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 3 month as first filed | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 6 month as first filed | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 9 month as first filed | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $2.01M 10-Q · filed 2026-08-12 | $3.57M 10-Q · filed 2026-08-12 | $5.23M derived: sum of 3 quarters · filed 2026-08-12 | $6.78M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2026-03-31 | $1.56M 10-Q · filed 2026-05-14 | $3.22M derived: sum of 2 quarters · filed 2026-05-14 | $4.77M derived: sum of 3 quarters · filed 2026-05-14 | $10.03M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-12-31 | $1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $3.21M derived: sum of 2 quarters · filed 2026-03-23 | $8.47M derived: sum of 3 quarters · filed 2026-08-12 | $14.01M 10-K · filed 2026-03-23 | |||
| 2025-09-30 | $1.55M 10-Q · filed 2025-11-06 | $6.82M derived: sum of 2 quarters · filed 2026-08-12 | $12.35M 10-Q · filed 2025-11-06 | $18.27M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-06-30 | $5.26M 10-Q · filed 2026-08-12 | $10.80M 10-Q · filed 2026-08-12 | $16.72M derived: sum of 3 quarters · filed 2026-08-12 | $23.26M derived: sum of 4 quarters · filed 2026-08-12 | |||
| 2025-03-31 | $5.54M 10-Q · filed 2026-05-14 | $11.45M derived: sum of 2 quarters · filed 2026-05-14 | $18.00M derived: sum of 3 quarters · filed 2026-05-14 | $24.16M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | $5.92M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $12.46M derived: sum of 2 quarters · filed 2026-03-23 | $18.62M derived: sum of 3 quarters · filed 2026-03-23 | $24.69M 10-K · filed 2026-03-23 | |||
| 2024-09-30 | $6.54M 10-Q · filed 2025-11-06 | $12.70M derived: sum of 2 quarters · filed 2025-11-06 | $18.77M 10-Q · filed 2025-11-06 | $25.00M derived: sum of 4 quarters · filed 2025-11-06 | |||
| 2024-06-30 | $6.16M 10-Q · filed 2025-08-07 | $12.23M 10-Q · filed 2025-08-07 | $18.45M derived: sum of 3 quarters · filed 2025-08-07 | $24.45M derived: sum of 4 quarters · filed 2025-08-07 | |||
| 2024-03-31 | $6.07M 10-Q · filed 2025-05-08 | $12.29M derived: sum of 2 quarters · filed 2025-05-08 | $18.29M derived: sum of 3 quarters · filed 2025-05-08 | $24.95M derived: sum of 4 quarters · filed 2025-05-08 | |||
| 2023-12-31 | $6.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $12.23M derived: sum of 2 quarters · filed 2025-03-13 | $18.89M derived: sum of 3 quarters · filed 2025-03-13 | $24.91M 10-K · filed 2025-03-13 | |||
| 2023-09-30 | $6.00M 10-Q · filed 2024-11-13 | $12.66M derived: sum of 2 quarters · filed 2024-11-13 | $18.68M 10-Q · filed 2024-11-13 | $24.54M derived: sum of 4 quarters · filed 2025-03-13 | |||
| 2023-06-30 | $6.66M 10-Q · filed 2024-08-13 | $12.68M 10-Q · filed 2024-08-13 | $18.53M derived: sum of 3 quarters · filed 2025-03-13 | $25.32M derived: sum of 4 quarters · filed 2025-03-13 | |||
| 2023-03-31 | $6.02M 10-Q · filed 2024-05-13 | $11.87M derived: sum of 2 quarters · filed 2025-03-13 | $18.66M derived: sum of 3 quarters · filed 2025-03-13 | $25.35M derived: sum of 4 quarters · filed 2025-03-13 | |||
| 2022-12-31 | $5.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $12.63M derived: sum of 2 quarters · filed 2025-03-13 | $19.33M derived: sum of 3 quarters · filed 2025-03-13 | $26.30M 10-K · filed 2025-03-13 | |||
| 2022-09-30 | $6.78M 10-Q · filed 2023-11-13 | $13.48M derived: sum of 2 quarters · filed 2023-11-13 | $20.45M 10-Q · filed 2023-11-13 | $27.34M derived: sum of 4 quarters · filed 2024-03-25 | |||
| 2022-06-30 | $6.70M 10-Q · filed 2023-08-10 | $13.67M 10-Q · filed 2023-08-10 | $20.56M derived: sum of 3 quarters · filed 2024-03-25 | $27.05M derived: sum of 4 quarters · filed 2024-03-25 | |||
| 2022-03-31 | $6.97M 10-Q · filed 2023-05-15 | $13.86M derived: sum of 2 quarters · filed 2024-03-25 | $20.36M derived: sum of 3 quarters · filed 2024-03-25 | $26.26M derived: sum of 4 quarters · filed 2024-03-25 | |||
| 2021-12-31 | $6.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $13.38M derived: sum of 2 quarters · filed 2024-03-25 | $19.29M derived: sum of 3 quarters · filed 2024-03-25 | $23.24M 10-K · filed 2024-03-25 | |||
| 2021-09-30 | $6.50M 10-Q · filed 2022-11-08 | $12.40M derived: sum of 2 quarters · filed 2022-11-08 | $16.35M 10-Q · filed 2022-11-08 | $19.44M derived: sum of 4 quarters · filed 2023-03-30 | |||
| 2021-06-30 | $5.91M 10-Q · filed 2022-08-08 | $9.86M 10-Q · filed 2022-08-08 | $12.95M derived: sum of 3 quarters · filed 2023-03-30 | $16.06M derived: sum of 4 quarters · filed 2023-03-30 | |||
| 2021-03-31 | $3.95M 10-Q · filed 2022-05-09 | $7.04M derived: sum of 2 quarters · filed 2023-03-30 | $10.15M derived: sum of 3 quarters · filed 2023-03-30 | $13.16M derived: sum of 4 quarters · filed 2023-03-30 | |||
| 2020-12-31 | $3.09M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $6.20M derived: sum of 2 quarters · filed 2023-03-30 | $9.21M derived: sum of 3 quarters · filed 2023-03-30 | $11.92M 10-K · filed 2023-03-30 | |||
| 2020-09-30 | $3.11M 10-Q · filed 2021-11-10 | $6.12M derived: sum of 2 quarters · filed 2021-11-10 | $8.83M 10-Q · filed 2021-11-10 | $11.51M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-06-30 | $3.01M 10-Q · filed 2021-08-09 | $5.72M 10-Q · filed 2021-08-09 | $8.40M derived: sum of 3 quarters · filed 2022-02-28 | $11.28M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2020-03-31 | $2.71M 10-Q · filed 2021-05-07 | $5.39M derived: sum of 2 quarters · filed 2022-02-28 | $8.27M derived: sum of 3 quarters · filed 2022-02-28 | $10.73M derived: sum of 4 quarters · filed 2022-02-28 | |||
| 2019-12-31 | $2.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $5.56M derived: sum of 2 quarters · filed 2022-02-28 | $8.03M derived: sum of 3 quarters · filed 2022-02-28 | $10.31M 10-K · filed 2022-02-28 | |||
| 2019-09-30 | $2.88M 10-Q · filed 2020-11-05 | $2.88K 10-Q · filed 2019-11-08 | $5.34M derived: sum of 2 quarters · filed 2020-11-05 | $7.63M 10-Q · filed 2020-11-05 | $7.63K 10-Q · filed 2019-11-08 | $10.50M derived: sum of 4 quarters · filed 2021-03-18 | |
| 2019-06-30 | $2.46M 10-Q · filed 2020-08-06 | $2.46K 10-Q · filed 2019-08-14 | $4.75M 10-Q · filed 2020-08-06 | $4.75K 10-Q · filed 2019-08-14 | $7.62M derived: sum of 3 quarters · filed 2021-03-18 | $7.62M derived: sum of 4 quarters · filed 2021-03-18 | |
| 2019-03-31 | $2.29M 10-Q · filed 2020-05-11 | $2.29K 10-Q · filed 2019-05-15 | $5.16M derived: sum of 2 quarters · filed 2021-03-18 | $5.16M derived: sum of 3 quarters · filed 2021-03-18 | $5.16M derived: sum of 4 quarters · filed 2021-03-18 | ||
| 2018-12-31 | $2.87M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $2.87M derived: sum of 2 quarters · filed 2021-03-18 | $2.87M derived: sum of 3 quarters · filed 2021-03-18 | $2.87M 10-K · filed 2021-03-18 | |||
| 2018-09-30 | $321.00 10-Q · filed 2019-11-08 | $553.00 derived: sum of 2 quarters · filed 2019-11-08 | $802.00 10-Q · filed 2019-11-08 | $1.39M derived: sum of 4 quarters · filed 2020-03-16 | |||
| 2018-06-30 | $232.00 10-Q · filed 2019-08-14 | $481.00 10-Q · filed 2019-08-14 | $1.39M derived: sum of 3 quarters · filed 2020-03-16 | $1.39M derived: sum of 4 quarters · filed 2020-03-16 | |||
| 2018-03-31 | $249.00 10-Q · filed 2019-05-15 | $1.39M derived: sum of 2 quarters · filed 2020-03-16 | $1.39M derived: sum of 3 quarters · filed 2020-03-16 | ||||
| 2017-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $1.39M derived: sum of 2 quarters · filed 2020-03-16 | $1.39M 10-K · filed 2020-03-16 | ||||
| 2017-09-30 | $593.00 10-Q · filed 2018-11-14 | $1.13K 10-Q · filed 2018-11-14 | |||||
| 2016-12-31 | $968.00K 10-K · filed 2019-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 |